• The Global HIV Vaccine Enterprise

    Uniting stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of—and future access to—an HIV vaccine

    Learn moreStrategic Plan
    Diagram of the plan

A renewed Strategic Plan

Uniting stakeholders to share knowledge, foster collaboration, enable solutions and to support the most critical issues, risks and challenges faced by the field

Increasing resources

Mobilizing new funding to support and grow the field of HIV vaccine research and development

Greater collaboration

Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts

News

IAS 2019: Promising HIV Vaccine Study Results Point to the Need to Intensify and Accelerate Preparation for Future Research and Access Challenges

/in /by

The Global HIV Vaccine Enterprise welcomes the important and encouraging results of the ASCENT study and new clinical data from the APPROACH study presented at the 10th IAS Conference on HIV Science (IAS 2019), held in Mexico City, Mexico. These two studies build on the success of previous research using mosaic-based vaccines and provide important data to inform ongoing efforts to develop an effective, implementable vaccine regimen – a central part of a comprehensive, global HIV prevention strategy.

Read more

Upcoming event

HIV Vaccine R&D at the IAS Science Conference 2019

/in /by

The IAS Conference on HIV Science is the world’s most influential meeting on HIV research and its applications. This biennial conference presents the critical advances in basic, clinical and operational research that moves science into policy and practice. Through its open and inclusive programme development, the meeting sets the gold standard of HIV research featuring highly diverse and cutting-edge studies.

HIV Vaccine research and development will be very much featured before and during the conference.

Read more

Timely topics

In 2012, the Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues.
Submit a timely topic

Portfolio

Newsletter

Sign up to receive the latest news of the Vaccine Enterprise and occasional information related to IAS activities related to vaccine research and development (Please read our Privacy Policy)